Propensity score methods for comparative-effectiveness analysis : A case study of direct oral anticoagulants in the atrial fibrillation population
OBJECTIVE: To explore methodological challenges when using real-world evidence (RWE) to estimate comparative-effectiveness in the context of Health Technology Assessment of direct oral anticoagulants (DOACs) in Scotland.
METHODS: We used linkage data from the Prescribing Information System (PIS), Scottish Morbidity Records (SMR) and mortality records for newly anticoagulated patients to explore methodological challenges in the use of Propensity score (PS) matching, Inverse Probability Weighting (IPW) and covariate adjustment with PS. Model performance was assessed by standardised difference. Clinical outcomes (stroke and major bleeding) and mortality were compared for all DOACs (including apixaban, dabigatran and rivaroxaban) versus warfarin. Patients were followed for 2 years from first oral anticoagulant prescription to first clinical event or death. Censoring was applied for treatment switching or discontinuation.
RESULTS: Overall, a good balance of patients' covariates was obtained with every PS model tested. IPW was found to be the best performing method in assessing covariate balance when applied to subgroups with relatively large sample sizes (combined-DOACs versus warfarin). With the IPTW-IPCW approach, the treatment effect tends to be larger, but still in line with the treatment effect estimated using other PS methods. Covariate adjustment with PS in the outcome model performed well when applied to subgroups with smaller sample sizes (dabigatran versus warfarin), as this method does not require further reduction of sample size, and trimming or truncation of extreme weights.
CONCLUSION: The choice of adequate PS methods may vary according to the characteristics of the data. If assumptions of unobserved confounding hold, multiple approaches should be identified and tested. PS based methods can be implemented using routinely collected linked data, thus supporting Health Technology decision-making.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
PloS one - 17(2022), 1 vom: 01., Seite e0262293 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ciminata, Giorgio [VerfasserIn] |
---|
Links: |
---|
Themen: |
5Q7ZVV76EI |
---|
Anmerkungen: |
Date Completed 22.02.2022 Date Revised 05.09.2022 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0262293 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM33607896X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM33607896X | ||
003 | DE-627 | ||
005 | 20231225231323.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0262293 |2 doi | |
028 | 5 | 2 | |a pubmed24n1120.xml |
035 | |a (DE-627)NLM33607896X | ||
035 | |a (NLM)35073380 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ciminata, Giorgio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Propensity score methods for comparative-effectiveness analysis |b A case study of direct oral anticoagulants in the atrial fibrillation population |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.02.2022 | ||
500 | |a Date Revised 05.09.2022 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: To explore methodological challenges when using real-world evidence (RWE) to estimate comparative-effectiveness in the context of Health Technology Assessment of direct oral anticoagulants (DOACs) in Scotland | ||
520 | |a METHODS: We used linkage data from the Prescribing Information System (PIS), Scottish Morbidity Records (SMR) and mortality records for newly anticoagulated patients to explore methodological challenges in the use of Propensity score (PS) matching, Inverse Probability Weighting (IPW) and covariate adjustment with PS. Model performance was assessed by standardised difference. Clinical outcomes (stroke and major bleeding) and mortality were compared for all DOACs (including apixaban, dabigatran and rivaroxaban) versus warfarin. Patients were followed for 2 years from first oral anticoagulant prescription to first clinical event or death. Censoring was applied for treatment switching or discontinuation | ||
520 | |a RESULTS: Overall, a good balance of patients' covariates was obtained with every PS model tested. IPW was found to be the best performing method in assessing covariate balance when applied to subgroups with relatively large sample sizes (combined-DOACs versus warfarin). With the IPTW-IPCW approach, the treatment effect tends to be larger, but still in line with the treatment effect estimated using other PS methods. Covariate adjustment with PS in the outcome model performed well when applied to subgroups with smaller sample sizes (dabigatran versus warfarin), as this method does not require further reduction of sample size, and trimming or truncation of extreme weights | ||
520 | |a CONCLUSION: The choice of adequate PS methods may vary according to the characteristics of the data. If assumptions of unobserved confounding hold, multiple approaches should be identified and tested. PS based methods can be implemented using routinely collected linked data, thus supporting Health Technology decision-making | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Anticoagulants |2 NLM | |
650 | 7 | |a Warfarin |2 NLM | |
650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
650 | 7 | |a Dabigatran |2 NLM | |
650 | 7 | |a I0VM4M70GC |2 NLM | |
700 | 1 | |a Geue, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Wu, Olivia |e verfasserin |4 aut | |
700 | 1 | |a Deidda, Manuela |e verfasserin |4 aut | |
700 | 1 | |a Kreif, Noemi |e verfasserin |4 aut | |
700 | 1 | |a Langhorne, Peter |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 17(2022), 1 vom: 01., Seite e0262293 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2022 |g number:1 |g day:01 |g pages:e0262293 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0262293 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2022 |e 1 |b 01 |h e0262293 |